Literature DB >> 19724749

Treatment of schizoaffective disorder.

Elisa Cascade1, Amir H Kalali, Peter Buckley.   

Abstract

In this article, we investigate the range of treatments prescribed for schizoaffective disorder. The data show that the majority of those treated, 87 percent, receive two or more pharmaceutical classes. From a therapeutic class perspective, 93 percent of schizoaffective disorder patients receive an antipsychotic, 48 percent receive a mood disorder treatment, and 42 percent receive an antidepressant. An expert commentary is also included.

Entities:  

Keywords:  antidepressant; antipsychotic; schizoaffective disorder

Year:  2009        PMID: 19724749      PMCID: PMC2719459     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  3 in total

1.  Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?

Authors:  Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

Review 2.  Major psychoses with mixed psychotic and mood symptoms: are mixed psychoses associated with different neurobiological markers?

Authors:  E Bora; M Yucel; A Fornito; M Berk; C Pantelis
Journal:  Acta Psychiatr Scand       Date:  2008-09       Impact factor: 6.392

Review 3.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

  3 in total
  6 in total

Review 1.  Antipsychotic Management of Schizoaffective Disorder: A Review.

Authors:  Jean-Pierre Lindenmayer; Amandeep Kaur
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

2.  Identification of Adverse Drug Events from Free Text Electronic Patient Records and Information in a Large Mental Health Case Register.

Authors:  Ehtesham Iqbal; Robbie Mallah; Richard George Jackson; Michael Ball; Zina M Ibrahim; Matthew Broadbent; Olubanke Dzahini; Robert Stewart; Caroline Johnston; Richard J B Dobson
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

Review 3.  A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder.

Authors:  Pierre Chue; James Chue
Journal:  Ther Clin Risk Manag       Date:  2016-01-27       Impact factor: 2.423

4.  Schizoaffective Disorder in an acute psychiatric unit: Profile of users and agreement with Operational Criteria (OPCRIT).

Authors:  Ryola Singh; Ugasvaree Subramaney
Journal:  S Afr J Psychiatr       Date:  2016-05-06       Impact factor: 1.550

5.  A group ICA based framework for evaluating resting fMRI markers when disease categories are unclear: application to schizophrenia, bipolar, and schizoaffective disorders.

Authors:  Yuhui Du; Godfrey D Pearlson; Jingyu Liu; Jing Sui; Qingbao Yu; Hao He; Eduardo Castro; Vince D Calhoun
Journal:  Neuroimage       Date:  2015-07-26       Impact factor: 6.556

6.  Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics.

Authors:  Antonio Ventriglio; Ross J Baldessarini; Giovanna Vitrani; Iris Bonfitto; Angela Chiara Cecere; Angelo Rinaldi; Annamaria Petito; Antonello Bellomo
Journal:  Front Psychiatry       Date:  2019-01-16       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.